<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740713</url>
  </required_header>
  <id_info>
    <org_study_id>DEEP-1</org_study_id>
    <nct_id>NCT01740713</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Deferiprone in Paediatric Patients</brief_title>
  <acronym>DEEP-1</acronym>
  <official_title>Multi-centre, Oral Single Dose Experimental and Modelling Study to Evaluate the Pharmacokinetics of Deferiprone in Patients Aged From 1 Month to Less Than 6 Years of Age Affected by Transfusion-dependent Haemoglobinopathies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorzio per Valutazioni Biologiche e Farmacologiche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Consorzio per Valutazioni Biologiche e Farmacologiche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deferiprone (DFP) is the most extensively studied oral iron chelator to date. It has been&#xD;
      authorised in Europe in 1999 for the treatment of iron overload in patients with&#xD;
      beta-thalassaemia major when DFO is contraindicated or inadequate. Despite a wide experience&#xD;
      of DFP there are limited experimental data available on DFP in children and no&#xD;
      pharmacokinetic data in children under 6 years of age. On the basis of the existing data in&#xD;
      adults and adolescent, in the DEEP-1 trial a pharmacokinetic bridging model was developed to&#xD;
      support the dose selection in children aged less than 6 years affected by transfusion&#xD;
      dependent haemoglobinopathies. The study consisted of two phases, namely an experimental&#xD;
      phase, during which patients received a single dose and a modeling phase, during which PK&#xD;
      data obtained after single dose in patients &lt; 6 years of age were analysed in conjunction&#xD;
      with historical PK data in adults and older children and adolescents. The model-based&#xD;
      analysis of the data obtained after single dose enabled the assessment of the dosing regimen&#xD;
      required for the purpose of accurate pharmacokinetic bridging. The ratio between the&#xD;
      predicted systemic exposure parameters (AUC and Cmax) in the target population and reference&#xD;
      group were used as basis for recommendation of the dose in the target population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deferiprone (DFP) was investigated as therapy for children from 1 month to less than 6 years&#xD;
      of age. The study was a multicenter randomised, single blind, and single dose PK study. The&#xD;
      patients were randomised according to a stratification scheme in which three different dose&#xD;
      levels were used.&#xD;
&#xD;
      Objectives: The primary objective of this study was to assess the pharmacokinetics of DFP in&#xD;
      paediatric patients aged from 1 month to less than 6 years.&#xD;
&#xD;
      The secondary objectives of this study were:&#xD;
&#xD;
        1. To identify dose levels yielding deferiprone exposures comparable to adults and define&#xD;
           the dose rationale in children aged from 1 month to less than 6 years.&#xD;
&#xD;
        2. To evaluate safety and tolerability of deferiprone after single dose administration in&#xD;
           children aged from 1 month to less than 6 years.&#xD;
&#xD;
        3. To evaluate the effect of demographic covariates on DFP disposition and estimate the&#xD;
           clearance distribution across the population.&#xD;
&#xD;
      Endpoints: The primary endpoints of the study were pharmacokinetic and included:&#xD;
&#xD;
        -  primary PK parameters: CL/F, Vd/F, Ka&#xD;
&#xD;
        -  secondary PK parameters: AUC, Cmax, Tmax, Css and Cmin.&#xD;
&#xD;
      Secondary endpoints were assessment of clinical safety and tolerability .&#xD;
&#xD;
      Methods: Twenty-three patients were enrolled and 18 of those ( 9 males and 9 females)&#xD;
      completed the study. The patients were administered at three dose levels ( 6 patients / each&#xD;
      dose):&#xD;
&#xD;
      Dose level 1: 8.3 mg/kg as a single dose (every 8 h) for a total daily dose of 25mg/kg Dose&#xD;
      level 2: 16.7 mg/kg as a single dose (every 8 h) for a total daily dose of 50 mg/kg Dose&#xD;
      level 3: 33.3 mg/kg as a single dose (every 8 h) for a total daily dose of 100 mg/kg&#xD;
&#xD;
      Blood samples for PK analysis were taken at 6 sampling time intervals, different depending on&#xD;
      the dose group: predose; in the range 10 -20 min; in the range 40-55min; in the range&#xD;
      1.05-1.15 h;in the range 1.25-5.30 h;in the range 6-8h after the first dose administration.&#xD;
      The concentration of deferiprone was determined by a validated HPLC method. A population PK&#xD;
      model approach was applied and the time course of deferiprone concentrations was analysed&#xD;
      with Nonlinear mixed effects modelling in NONMEM, version 7.2.0. Model building included the&#xD;
      assessment of the influence of relevant demographic covariates (i.e:body weight , age,&#xD;
      height) on the disposition of deferiprone.&#xD;
&#xD;
      Using the pharmacokinetic model developed for the paediatric population in this study in&#xD;
      conjunction with a model previously developed for 55 adult subjects , simulations were&#xD;
      performed to evaluate drug exposure in children below 6 years of age and across a standard&#xD;
      thalassaemic adult population.&#xD;
&#xD;
      Descriptive statistics were used to summarise adverse events, vital signs and clinical lab&#xD;
      data (haematology, biochemistry and virology)&#xD;
&#xD;
      Results: A one-compartment model with first-order absorption was found to best describe the&#xD;
      disposition of deferiprone. The choice of three dose levels enable to assess linearity of&#xD;
      pharmacokinetic across the dose range. The disposition parameters estimated through the&#xD;
      pop-PK model included CL/F , V/F. In addition to the final model parameter estimates, the&#xD;
      secondary pharmacokinetic parameters were derived based on the individual predicted&#xD;
      concentration vs. time profiles and were summarised per dose level.&#xD;
&#xD;
      Body weight was found to be a good predictor of inter-individual differences in the&#xD;
      population under investigation.&#xD;
&#xD;
      As expected from the known safety profile of the drug, no Serious Adverse Events were&#xD;
      observed during the DEEP-1 PK Study.&#xD;
&#xD;
      Based on the simulation analysis performed, a similar exposure is achieved in adults and&#xD;
      children in terms of AUC and Css when receiving the current dosing regimen both at 75 and 100&#xD;
      mg/kg/day, while a considerable increase in Cmax was observed in children when compared to&#xD;
      the adult population. However, exposure is the parameter related to clinical response rather&#xD;
      than Cmax. Indeed, simulations suggested that a dosing regimen of 25 mg/kg t.i.d. (75&#xD;
      mg/kg/day) is recommended for children aged from 1 month to &lt; 6 years, with the possibility&#xD;
      of titration up to 33.3 mg/kg t.i.d. (100 mg/kg/day), if necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>Plasma clearance after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-8h)</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>Area under concentration versus time curve from 0 to 8 h post dosing. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>V/F</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>volume of distribution after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>Time at which the maximum concentration (Cmax) is reached. Secondary pharmacokinetic parameters such as Cmax, Min, Tmax, Css and AUC (0-8h) were derived based on the individual predicted concentration vs. time profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ka</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>Absorption rate constant. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>Maximum concentration reached in plasma. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Css</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>Plasma concentration reached at steady state. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin</measure>
    <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
    <description>Minimum plasma concentration. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from drug administration up to 8 days post treatment</time_frame>
    <description>All the medical occurrences that started after the administration of the drug</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Chronic Iron Overload</condition>
  <arm_group>
    <arm_group_label>Deferiprone, dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferiprone, dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferiprone, dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone, dose level 1</intervention_name>
    <description>a solution at 80 mg/mL will be administered orally</description>
    <arm_group_label>Deferiprone, dose level 1</arm_group_label>
    <other_name>DFP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone, dose level 2</intervention_name>
    <description>a solution at 80 mg/mL will be administered orally</description>
    <arm_group_label>Deferiprone, dose level 2</arm_group_label>
    <other_name>DFP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone, dose level 3</intervention_name>
    <description>a solution at 80 mg/mL will be administered orally</description>
    <arm_group_label>Deferiprone, dose level 3</arm_group_label>
    <other_name>DFP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in a chronic transfusional program who have received at least 150 ml/kg/year&#xD;
             of packed red blood cells (corresponding approximately to 12 transfusions) and on&#xD;
             current treatment with DFO, DFX, DFP; aged from 1 month to less than 6 years; or&#xD;
&#xD;
          -  Patients na√Øve to any chelation treatment who have received not less than 150 ml/kg of&#xD;
             packed red blood cells (corresponding to approximately 12 transfusions) and have&#xD;
             ferritin levels &gt; 800 ng/mL, aged from 1 month to less than 6 years; or&#xD;
&#xD;
          -  Patients who meet the transfusion criteria (150 ml/kg/year corresponding approximately&#xD;
             to 12 transfusions) and have known intolerance or contraindication to DFO&#xD;
&#xD;
        And if all of the following criteria apply:&#xD;
&#xD;
          -  Patients affected by any hereditary haemoglobinopathies requiring chronic transfusion&#xD;
             therapy including but not limited to thalassaemia and sickle cell disease&#xD;
&#xD;
          -  Written informed consent obtained from their legal guardian on the patient's behalf in&#xD;
             accordance with the national legislations. According to his/her capability, patient's&#xD;
             informed assent will be collected&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with known intolerance or contraindication to the trial treatment&#xD;
&#xD;
          -  Patient with Hb levels less than 8g/dl (entry may be delayed until values return to&#xD;
             normal)&#xD;
&#xD;
          -  Patient with platelet count &lt;100.000/mm3 or absolute neutrophil count &lt;1.500/mm3&#xD;
             (entry may be delayed until values return to normal)&#xD;
&#xD;
          -  Patient with evidence of abnormal liver function (ALT level &gt;5 times the upper normal&#xD;
             limit during six months preceding enrolment; entry may be delayed until values return&#xD;
             to normal)&#xD;
&#xD;
          -  iron overload from causes other than transfusional haemosiderosis&#xD;
&#xD;
          -  severe heart dysfunction secondary to iron overload defined as the occurrence of heart&#xD;
             failure or severe arrhythmia or as indicated by cardiac T2* lower than 10 ms, if&#xD;
             recent MRI data is available,&#xD;
&#xD;
          -  Patient with serum creatinine level above the upper normal limit at screening; entry&#xD;
             may be delayed until values return to normal.&#xD;
&#xD;
          -  Serological evidence of chronic hepatitis B (presence of HBe Ag, HBsAg, HBcAb-IgM, in&#xD;
             the absence of HBsAb).&#xD;
&#xD;
          -  History of significant medical or psychiatric disorder that may impair compliance with&#xD;
             the requirements of the protocol.&#xD;
&#xD;
          -  The patient has received another investigational drug within 30 days prior to this&#xD;
             study.&#xD;
&#xD;
          -  Patient with a pre-existing condition or any other surgical or medical condition which&#xD;
             might significantly interfere with normal gastrointestinal and hepatic function that&#xD;
             could alter the absorption, metabolism, and/or excretion of the study drug.&#xD;
&#xD;
          -  Patient with a known history of HIV seropositivity.&#xD;
&#xD;
          -  Fever and other signs/symptoms of infection in the 10 days before drug&#xD;
             administration(treatment day)&#xD;
&#xD;
          -  Concomitant use of other iron chelators or trivalent cation-dependent medicinal&#xD;
             products such as aluminium-based antacids.&#xD;
&#xD;
          -  Patient with a chronic condition that does not allow suspension of related treatment&#xD;
             from starting of washout until drug is administered.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Della Pasqua</last_name>
    <role>Study Chair</role>
    <affiliation>Universiteit Leiden, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Carlo Del Vecchio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medical and Public Health Services of the Ministry of Health</name>
      <address>
        <city>Nicosia</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo Univesity Paediatric Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Consorziale</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Antonio Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica Universita' - Asl 1</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cyprus</country>
    <country>Egypt</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>November 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <results_first_submitted>March 4, 2016</results_first_submitted>
  <results_first_submitted_qc>November 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2017</results_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic iron overload</keyword>
  <keyword>hereditary haemoglobinopathy</keyword>
  <keyword>beta thalassaemia major</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 23 children affected by transfusion-dependent haemoglobinopathies were enrolled in this study. Of these 23 children, 2 were screening failures and 3 early terminations.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Deferiprone 25 mg/kg/Day</title>
          <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
        <group group_id="P2">
          <title>Deferiprone 50 mg/kg/da</title>
          <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
        <group group_id="P3">
          <title>Deferiprone 100 mg/kg/Day</title>
          <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Deferiprone 25 mg/kg/Day</title>
          <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
        <group group_id="B2">
          <title>Deferiprone 50 mg/kg/Day</title>
          <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
        <group group_id="B3">
          <title>Deferiprone 100 mg/kg/Day</title>
          <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CL/F</title>
        <description>Plasma clearance after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population</title>
            <description>Deferiprone liquid oral solution (80 mg/ml) has been administered at 25/50/100 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F</title>
          <description>Plasma clearance after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.</description>
          <units>litre/h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="0.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-8h)</title>
        <description>Area under concentration versus time curve from 0 to 8 h post dosing. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone 25 mg/kg/Day</title>
            <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O2">
            <title>Deferiprone 50 mg/kg/Day</title>
            <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O3">
            <title>Deferiprone 100 mg/kg/Day</title>
            <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-8h)</title>
          <description>Area under concentration versus time curve from 0 to 8 h post dosing. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
          <units>micromol*h/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.7" lower_limit="90.6" upper_limit="129.0"/>
                    <measurement group_id="O2" value="210.0" lower_limit="173.1" upper_limit="266.6"/>
                    <measurement group_id="O3" value="428.8" lower_limit="291.4" upper_limit="547.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>V/F</title>
        <description>volume of distribution after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population</title>
            <description>Deferiprone liquid oral solution (80 mg/ml) has been administered at 25/50/100 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>V/F</title>
          <description>volume of distribution after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age</description>
          <units>litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time at which the maximum concentration (Cmax) is reached. Secondary pharmacokinetic parameters such as Cmax, Min, Tmax, Css and AUC (0-8h) were derived based on the individual predicted concentration vs. time profiles.</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone 25 mg/kg/Day</title>
            <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O2">
            <title>Deferiprone 50 mg/kg/Day</title>
            <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O3">
            <title>Deferiprone 100 mg/kg/Day</title>
            <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time at which the maximum concentration (Cmax) is reached. Secondary pharmacokinetic parameters such as Cmax, Min, Tmax, Css and AUC (0-8h) were derived based on the individual predicted concentration vs. time profiles.</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.19" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.33" lower_limit="0.21" upper_limit="0.63"/>
                    <measurement group_id="O3" value="0.37" lower_limit="0.27" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ka</title>
        <description>Absorption rate constant. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population</title>
            <description>Deferiprone liquid oral solution (80 mg/ml) has been administered at 25/50/100 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Ka</title>
          <description>Absorption rate constant. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.</description>
          <units>h^-1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum concentration reached in plasma. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone 25 mg/kg/Day</title>
            <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O2">
            <title>Deferiprone 50 mg/kg/Day</title>
            <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O3">
            <title>Deferiprone 100 mg/kg/Day</title>
            <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum concentration reached in plasma. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
          <units>microM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" lower_limit="45.1" upper_limit="80.7"/>
                    <measurement group_id="O2" value="119.8" lower_limit="106" upper_limit="154"/>
                    <measurement group_id="O3" value="229.5" lower_limit="179.7" upper_limit="278.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Css</title>
        <description>Plasma concentration reached at steady state. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone 25 mg/kg/Day</title>
            <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O2">
            <title>Deferiprone 50 mg/kg/Day</title>
            <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O3">
            <title>Deferiprone 100 mg/kg/Day</title>
            <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Css</title>
          <description>Plasma concentration reached at steady state. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
          <units>microM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.6" upper_limit="2.3"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.1" upper_limit="4.9"/>
                    <measurement group_id="O3" value="7.7" lower_limit="5.1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin</title>
        <description>Minimum plasma concentration. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
        <time_frame>Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferiprone 25 mg/kg/Day</title>
            <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O2">
            <title>Deferiprone 50 mg/kg/Day</title>
            <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
          <group group_id="O3">
            <title>Deferiprone 100 mg/kg/Day</title>
            <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin</title>
          <description>Minimum plasma concentration. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.</description>
          <units>microM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.92" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.79" upper_limit="5.5"/>
                    <measurement group_id="O3" value="6.8" lower_limit="3.1" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>All the medical occurrences that started after the administration of the drug</description>
        <time_frame>from drug administration up to 8 days post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>patients who may experience adverse events occurred before or after treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>All the medical occurrences that started after the administration of the drug</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All the medical occurrences that started after the administration of the drug under investigation have been recorded as AEs till the follow -up visit at 8 days post dosing.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Deferiprone 25mg/kg/Day</title>
          <description>Deferiprone will be administered at 25 mg/kg/day&#xD;
Deferiprone, dose level 1: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
        <group group_id="E2">
          <title>Deferiprone 50 mg/kg/Day</title>
          <description>Deferiprone will be administered at 50 mg/kg/day&#xD;
Deferiprone, dose level 2: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
        <group group_id="E3">
          <title>Deferiprone 100 mg/kg/Day</title>
          <description>Deferiprone will be administered at 100 mg/kg/day&#xD;
Deferiprone, dose level 3: deferiprone liquid oral solution (80 mg/ml)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Infantile spitting up</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash trunk</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Coordinator</name_or_title>
      <organization>Consorzio per Valutazioni Biologiche e Farmacologiche</organization>
      <phone>0039 0382 25075</phone>
      <email>mariagraziafelisi@cvbf.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

